Top Markets
Coin of the day
Cyteir Therapeutics, Inc. Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc.

CYT
Rank in Stocks #21570
Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated... Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to innovating and bringing to market cutting-edge precision oncology medicines. Its flagship compound, CYT-0851, is an novel, orally administered small molecule drug candidate, designed for once-daily dosing. This therapy is currently undergoing Phase I/II clinical evaluations, both as a standalone treatment and in combination with other drugs, targeting a broad range of solid tumors and hematologic malignancies. Furthermore, the company is advancing CYT-1853, another promising candidate in preclinical development for similar oncological indications. Cyteir Therapeutics was established in 2012 and is headquartered in Lexington, Massachusetts.
Share Price
$3.01
Last synced: 2024-04-12
Market Cap
$104.64M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Cyteir Therapeutics, Inc. (CYT)

Category

Earnings for Cyteir Therapeutics, Inc. (CYT)
Earnings in 2026 TTM: 0
According to Cyteir Therapeutics, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Cyteir Therapeutics, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$-4.02B -
AU
- -
CH